Commerzbank Aktiengesellschaft FI lifted its stake in Eli Lilly and Co (NYSE:LLY) by 6.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 111,680 shares of the company’s stock after acquiring an additional 7,106 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Eli Lilly and were worth $9,553,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in Eli Lilly and by 2,628.5% during the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after buying an additional 59,978,664 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Eli Lilly and by 7,093.5% in the second quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock valued at $769,774,000 after purchasing an additional 9,223,251 shares during the last quarter. Dodge & Cox grew its position in shares of Eli Lilly and by 22,094.9% in the second quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock valued at $493,138,000 after purchasing an additional 5,964,955 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Eli Lilly and by 91.1% in the second quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock valued at $468,691,000 after purchasing an additional 2,714,505 shares during the last quarter. Finally, Winslow Capital Management LLC grew its position in shares of Eli Lilly and by 79.7% in the first quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock valued at $326,008,000 after purchasing an additional 1,719,538 shares during the last quarter. 76.31% of the stock is currently owned by institutional investors and hedge funds.
Eli Lilly and Co (NYSE LLY) opened at $86.98 on Friday. The stock has a market cap of $95,770.00, a price-to-earnings ratio of 41.42, a PEG ratio of 1.62 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. Eli Lilly and Co has a 1-year low of $74.00 and a 1-year high of $89.09.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.88 earnings per share. research analysts predict that Eli Lilly and Co will post 4.22 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. The ex-dividend date is Wednesday, February 14th. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a dividend yield of 2.59%. Eli Lilly and’s dividend payout ratio is 99.05%.
In related news, SVP Alfonso G. Zulueta sold 2,003 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares in the company, valued at $3,646,338.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jeffrey N. Simmons sold 12,500 shares of the stock in a transaction on Monday, December 11th. The shares were sold at an average price of $86.46, for a total value of $1,080,750.00. Following the completion of the sale, the senior vice president now owns 124,522 shares of the company’s stock, valued at $10,766,172.12. The disclosure for this sale can be found here. Insiders have sold 251,088 shares of company stock valued at $22,041,236 over the last quarter. Company insiders own 0.20% of the company’s stock.
Several equities analysts have recently commented on the company. BMO Capital Markets reaffirmed a “sell” rating and issued a $71.00 target price on shares of Eli Lilly and in a research report on Thursday, September 28th. Cowen reaffirmed a “buy” rating and issued a $95.00 target price on shares of Eli Lilly and in a research report on Wednesday, October 4th. Piper Jaffray Companies reiterated a “buy” rating and issued a $105.00 price target on shares of Eli Lilly and in a research note on Friday, October 13th. Morgan Stanley set a $86.00 price target on Eli Lilly and and gave the company a “hold” rating in a research note on Friday, October 6th. Finally, Goldman Sachs Group reiterated a “buy” rating and issued a $95.00 price target (up from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $92.14.
ILLEGAL ACTIVITY NOTICE: “Eli Lilly and Co (LLY) Shares Bought by Commerzbank Aktiengesellschaft FI” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/14/commerzbank-aktiengesellschaft-fi-increases-position-in-eli-lilly-and-co-lly.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.